Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Sponsored Content

RYBELSUS® – Semaglutide as the world’s first and only oral GLP-1 analogue

    • Endocrinology and Diabetology
    • RX
  • 3 minute read

People with type 2 diabetes have too little endogenous GLP-1 (glucagon-like peptide 1) or its effect is reduced. Semaglutide, which mimics natural GLP-1, can compensate for this.1,2 It lowers blood glucose, supports weight loss and reduction of cardiovascular burden.1,2,* RYBELSUS® (Semaglutide) is approved in Switzerland as the world’s first and only oral GLP-1 analog for patients with inadequately controlled T2DM.1

When we eat, our intestines produce a substance called GLP-1. This stimulates the secretion of insulin in the pancreas in a glucose-dependent manner and inhibits that of glucagon. In addition, GLP-1 slows gastric emptying, increases the feeling of satiety and centrally regulates cravings. This prevents the blood sugar from rising too high.

In patients with type 2 diabetes, too little GLP-1 is probably released or its effect is impaired, which increases the blood glucose level and subsequently also the long-term blood glucose value HbA1C. The latter is a risk factor for various secondary diseases.

Semaglutide – a modern and potent GLP-1 analogue

Semaglutide is a modern and potent GLP-1 analogue that mimics natural GLP-1.1,2 The optimized active ingredient is degraded in a delayed manner, which prolongs its duration of action and opens up new application possibilities.4 Semaglutide can do the following:

  • It lowers elevated blood glucose in a glucose-dependent manner, thereby significantly lowering patients’ HbA1C.1,2
  • By regulating the feeling of satiety and hunger, it can lead to weight loss.1,2,*

All of this helps patients with inadequately controlled type 2 diabetes and obesity (BMI ≥ 28) achieve their treatment goals and prevent microvascular and macrovascular sequelae thanks to Semaglutide.1,2,* For these patients, a reduction in their cardiovascular burden is of key importance (prevention of myocardial infarction, stroke, etc.).3

The PIONEER 6 clinical trial of the cardiovascular outcome of oral semaglutide demonstrated a numerically reduced cardiovascular risk (vs. placebo).1,5,*

Semaglutide (RYBELSUS®) as the world’s first and only oral GLP-1 analogue

In diabetes therapy, a departure for new shores is now beginning. Since April 2020, RYBELSUS® has been approved by Swissmedic in Switzerland for patients with T2DM, as the world’s first and only oral GLP-1 analog. The good efficacy of Semaglutide is opened up to an even larger group of patients via the simple administration of RYBELSUS®: This allows a choice between a once-daily RYBELSUS® tablet and the once-weekly subcutaneous Ozempic®.1,2 With RYBELSUS® , 7 out of 10 patients achieve a treatment target of HbA1C ≤7 %, with a sustained effect.1 This and the consistent weight loss under RYBELSUS® is significantly better compared to other modern antidiabetic drugs.1,*,**

The individually tunable patient benefit enables the optimization of compliance and thus effective prevention of secondary diseases.6

* RYBELSUS® and Ozempic® are indicated for the treatment of inadequately controlled type 2 diabetes mellitus in addition to diet and exercise, but are not indicated for weight loss or reduction of cardiovascular events.

** Clinical trials showed significantly better glycemic control (baseline HbA1C during study duration) and weight reduction (change in body weight during study duration) for semaglutide vs. placebo (PIONEER 8)1,7, vs. empagliflozin (PIONEER 2)1,8, vs. sitagliptin (PIONEER 3 and PIONEER 7)1,9,10, and vs. liraglutide (PIONEER 4)1,11.

Abbreviations: CVOT: cardiovascular outcome study; GLP-1: glucagon-like peptide 1; T2DM: type 2 diabetes.

References

1. Rybelsus® Professional Information, www.swissmedicinfo.ch.
2. Ozempic® SmPC, www.swissmedicinfo.ch.
3rd SGED/SSED Working Group. Recommendations of the Swiss Society of Endocrinology and Diabetology (SGED/SSED) for the treatment of type 2 diabetes mellitus (2020). Status: January 23, 2020. Available at: https://www.sgedssed.ch/fileadmin/user_upload/6_Diabetologie/61_Empfehlungen_Facharzt/-2020_Swiss_Recomm_Medis_DE_def.pdf, last accessed 05/2020.
4. Lau et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015; 58:7370-80.
5 Husain et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-51.
6. Polonsky et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab. 2011;13(2):144-9.
7. Zinman et al. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. Diabetes Care. 2019;42(12):2262-71.
8. Rodbard et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272-81.
9. Rosenstock et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019;321(15):1466-80.
10 Pieber et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528-39.
11 Pratley et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39-50.
 
Short Subject Information
Freigabenummer CH21RYB00148_03/2021
Partner
  • nn_logo_cmyk_blue_large
Previous Article
  • New cellular protection mechanism

Controlled scarring in the brain

  • Anesthesiology
  • RX
View Post
Next Article
  • Diabetes mellitus

Biomarker-associated clustering for improved treatment management.

  • Cardiology
  • Congress Reports
  • Endocrinology and Diabetology
  • Partner Content
  • RX
  • Studies
View Post
You May Also Like
View Post
  • 4 min
  • Guideline update

Dietary recommendations for Crohn’s disease and colitis

    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 4 min
  • Circadian rhythm during Ramadan

Disturbed sleep patterns lead to metabolic stress

    • Education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • RX
    • Studies
View Post
  • 6 min
  • Case Report

Breast cancer metastases in the bladder

    • Cases
    • Education
    • Gynecology
    • Oncology
    • RX
    • Urology
View Post
  • 11 min
  • Findings from the ALS Symposium 2024 in Montreal

Current and future approaches in the treatment of amyotrophic lateral sclerosis (ALS)

    • Congress Reports
    • Interviews
    • Neurology
    • RX
    • Studies
View Post
  • 8 min
  • Efficacy, mechanism of action and clinical effects

Garlic and high blood pressure

    • Cardiology
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 7 min
  • Moderate to severe chronic hand eczema

Delgocitinib cream – first topical pan-JAK inhibitor approved in Switzerland

    • Allergology and clinical immunology
    • Dermatology and venereology
    • Education
    • Infectiology
    • Market & Medicine
    • Pharmacology and toxicology
    • RX
View Post
  • 9 min
  • Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CA)

Diagnosis at an early stage, prognostic classifications and outlook

    • Cardiology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Case report: Drug-induced hepatitis

Rare side effect of tirzepatide therapy

    • Cases
    • Education
    • Endocrinology and Diabetology
    • Gastroenterology and Hepatology
    • Pharmacology and toxicology
    • RX
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Patience, knowledge and persistence in therapy
  • 2
    Sarcopenia and malnutrition in the context of pneumological rehabilitation
  • 3
    Medical and psychosocial perspectives
  • 4
    New nomenclature for non-alcoholic fatty liver disease
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.